PMV Pharmaceuticals, Inc. (NASDAQ:PMVP) Shares Sold by Assenagon Asset Management S.A.

Assenagon Asset Management S.A. cut its holdings in PMV Pharmaceuticals, Inc. (NASDAQ:PMVP) by 72.6% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 70,814 shares of the company’s stock after selling 187,724 shares during the period. Assenagon Asset Management S.A. owned 0.14% of PMV Pharmaceuticals worth $220,000 at the end of the most recent reporting period.

A number of other large investors have also recently added to or reduced their stakes in the business. Swiss National Bank lifted its stake in PMV Pharmaceuticals by 8.5% during the first quarter. Swiss National Bank now owns 26,800 shares of the company’s stock worth $558,000 after purchasing an additional 2,100 shares in the last quarter. US Bancorp DE lifted its stake in PMV Pharmaceuticals by 2,588.0% during the first quarter. US Bancorp DE now owns 2,016 shares of the company’s stock worth $42,000 after purchasing an additional 1,941 shares in the last quarter. MetLife Investment Management LLC lifted its stake in PMV Pharmaceuticals by 58.5% during the first quarter. MetLife Investment Management LLC now owns 16,818 shares of the company’s stock worth $350,000 after purchasing an additional 6,207 shares in the last quarter. Rhumbline Advisers lifted its stake in PMV Pharmaceuticals by 7.7% during the first quarter. Rhumbline Advisers now owns 27,690 shares of the company’s stock worth $577,000 after purchasing an additional 1,983 shares in the last quarter. Finally, BlackRock Inc. lifted its stake in PMV Pharmaceuticals by 4.0% during the first quarter. BlackRock Inc. now owns 2,640,350 shares of the company’s stock worth $54,970,000 after purchasing an additional 100,526 shares in the last quarter. 90.20% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of research analysts have commented on the company. HC Wainwright restated a “buy” rating and set a $5.00 price target on shares of PMV Pharmaceuticals in a research note on Thursday, March 7th. LADENBURG THALM/SH SH began coverage on PMV Pharmaceuticals in a research note on Wednesday, December 27th. They set a “buy” rating and a $7.00 price target on the stock.

PMV Pharmaceuticals Trading Down 2.5 %

Shares of NASDAQ PMVP opened at $1.56 on Tuesday. The stock has a market cap of $80.25 million, a P/E ratio of -1.08 and a beta of 1.65. PMV Pharmaceuticals, Inc. has a 12-month low of $1.18 and a 12-month high of $9.72. The business’s fifty day simple moving average is $1.71 and its 200-day simple moving average is $2.40.

PMV Pharmaceuticals (NASDAQ:PMVP) last announced its quarterly earnings data on Thursday, February 29th. The company reported ($0.31) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.39) by $0.08. On average, equities analysts forecast that PMV Pharmaceuticals, Inc. will post -1.47 EPS for the current fiscal year.

PMV Pharmaceuticals Profile

PMV Pharmaceuticals, Inc, a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. It's lead product candidate is PC14586, a small molecule that corrects mutant p53 protein containing the Y220C mutation and restores wild-type p53 function.